ArticleParasites & vectors2025
Antibody responses to gSG6-p1, AgSAP, and SAMSP1 following anopheline salivary exposure.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessment of antibody responses to Anopheles SG6-P1 and Aedes N-term 34 kDa salivary peptides: a randomised human-challenge trial of controlled exposures to vector bites.BMC medicine · 2026Trial
- Specificity of Phlebotomus papatasi and Phlebotomus tobbi recombinant salivary proteins developed as serological surveillance tool.Parasites & vectors · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
backgroundCurrent methods to determine exposure to malaria-infected mosquitoes via entomologic investigations are technically challenging and can be inaccurate in low transmission settings. Antibody responses to mosquito salivary antigens (MSA) such as gSG6-p1 have been used as biomarkers of exposure to Anopheles mosquito bites, while newer MSA that are specifically associated with Plasmodium infection show promise for malaria vector exposure.
methodsThis study investigates two novel Anopheles gambiae salivary antigens, AgSAP and SAMSP1, as potential biomarkers of malaria vector exposure. We evaluated the humoral response to gSG6-p1, SAMSP1, and AgSAP in a murine model and in malaria-exposed individuals with submicroscopic parasitemia across different malaria endemicity areas, seasons, and infection statuses in coastal Tanzania. We also analyzed antibody kinetics following direct skin feeding assays carried out using uninfected colony-reared An. gambiae.
resultsGSG6-p1, AgSAP, and SAMSP1 levels were all higher in individuals with submicroscopic malaria compared with endemic controls, and there was increased reactivity for AgSAP and gSG6-p1 in the villages with higher malaria prevalence, though most of these findings were only borderline significant. Meanwhile, SAMSP1 was the only MSA that induced a significantly higher humoral response during the rainy season, perhaps due to greater sequence identity of this MSA across multiple Anopheles species. GSG6-p1, AgSAP, and SAMSP1 levels increased in mice at 8 weeks after weekly mosquito feedings. However, human gSG6-p1 and AgSAP levels were paradoxically lower 4 weeks after direct skin feeding assays.
conclusionsMosquito salivary antigens associated with Plasmodium infection such as AgSAP and SAMSP1 show promise as biomarkers of malaria vector exposure. However, the dynamics of immunoglobulin (Ig)G response against AgSAP and SAMSP1 after mosquito bites requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.